Protagonist Therapeutics, Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Protagonist Therapeutics, Inc (PTGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $39.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-25
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $39.10M, a 3.93% decline from fiscal 2024.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $40.70M, a 1133.33% increase from fiscal 2023.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $3.30M, a 38.89% decline from fiscal 2022.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $5.40M, a 48.57% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $39.10M 10-K · filed 2026-02-25 |
| 2024-12-31 | $40.70M 10-K · filed 2026-02-25 |
| 2023-12-31 | $3.30M 10-K · filed 2026-02-25 |
| 2022-12-31 | $5.40M 10-K · filed 2025-02-21 |
| 2021-12-31 | $10.50M 10-K · filed 2024-02-27 |
| 2020-12-31 | $3.00M 10-K · filed 2023-03-15 |
| 2019-12-31 | $2.60M 10-K · filed 2022-02-28 |
| 2018-12-31 | $1.30M 10-K · filed 2021-03-10 |
| 2017-12-31 | $3.50M 10-K · filed 2020-03-10 |
| 2016-12-31 | $169.00K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |